Navigating precision: the crucial role of next-generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor-positive, human epidermal growth factor Receptor2-negative early breast cancer
Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer is the most common subtype, representing over two-thirds of new diagnoses. Adjuvant therapy, which encompasses various medications and treatment durations, is the standard approach for managing ea...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Cancer Biology & Therapy |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/15384047.2024.2405060 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846126046016962560 |
|---|---|
| author | Ying Xu Yingxue Qi Zhongyu Lu Yuan Tan Dongsheng Chen Haijun Luo |
| author_facet | Ying Xu Yingxue Qi Zhongyu Lu Yuan Tan Dongsheng Chen Haijun Luo |
| author_sort | Ying Xu |
| collection | DOAJ |
| description | Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer is the most common subtype, representing over two-thirds of new diagnoses. Adjuvant therapy, which encompasses various medications and treatment durations, is the standard approach for managing early stage HR+ HER2- breast cancer. Optimizing treatment is essential to minimize unnecessary side effects while addressing the biological variability inherent in HR+/HER2− breast cancers. Incorporating biological biomarkers into treatment decisions, alongside traditional clinical factors, is vital. Gene expression assays can identify patients unlikely to benefit from adjuvant chemotherapy, thereby refining treatment strategies and improving risk assessment. This paper reviews evidence for several genomic tests, including Oncotype DX, MammaPrint, Breast Cancer Index, RucurIndex, and EndoPredict, which assist in tailoring adjuvant therapy. Additionally, we explore the role of liquid biopsies in personalizing treatment, emphasizing the importance of considering late relapse risks and potential benefits of extended systemic therapy for HR+/HER2− breast cancer patients. |
| format | Article |
| id | doaj-art-32cdd99ecadd4fe3a5de98c79a4502cb |
| institution | Kabale University |
| issn | 1538-4047 1555-8576 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Cancer Biology & Therapy |
| spelling | doaj-art-32cdd99ecadd4fe3a5de98c79a4502cb2024-12-13T06:53:24ZengTaylor & Francis GroupCancer Biology & Therapy1538-40471555-85762024-12-0125110.1080/15384047.2024.2405060Navigating precision: the crucial role of next-generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor-positive, human epidermal growth factor Receptor2-negative early breast cancerYing Xu0Yingxue Qi1Zhongyu Lu2Yuan Tan3Dongsheng Chen4Haijun Luo5Department of Obestetrics and Gynecology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, ChinaThe Medical Department, Jiangsu Simcere Diagnostics Co. Ltd. Nanjing Simcere Medical Laboratory Science Co. Ltd., The State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, ChinaThe Medical Department, Jiangsu Simcere Diagnostics Co. Ltd. Nanjing Simcere Medical Laboratory Science Co. Ltd., The State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, ChinaThe Medical Department, Jiangsu Simcere Diagnostics Co. Ltd. Nanjing Simcere Medical Laboratory Science Co. Ltd., The State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, ChinaThe Medical Department, Jiangsu Simcere Diagnostics Co. Ltd. Nanjing Simcere Medical Laboratory Science Co. Ltd., The State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, ChinaDepartment of Pathology, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, ChinaHormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer is the most common subtype, representing over two-thirds of new diagnoses. Adjuvant therapy, which encompasses various medications and treatment durations, is the standard approach for managing early stage HR+ HER2- breast cancer. Optimizing treatment is essential to minimize unnecessary side effects while addressing the biological variability inherent in HR+/HER2− breast cancers. Incorporating biological biomarkers into treatment decisions, alongside traditional clinical factors, is vital. Gene expression assays can identify patients unlikely to benefit from adjuvant chemotherapy, thereby refining treatment strategies and improving risk assessment. This paper reviews evidence for several genomic tests, including Oncotype DX, MammaPrint, Breast Cancer Index, RucurIndex, and EndoPredict, which assist in tailoring adjuvant therapy. Additionally, we explore the role of liquid biopsies in personalizing treatment, emphasizing the importance of considering late relapse risks and potential benefits of extended systemic therapy for HR+/HER2− breast cancer patients.https://www.tandfonline.com/doi/10.1080/15384047.2024.2405060Early breast cancerHR-positiveHER2-negativeadjuvant therapyrecurrence risk assessment |
| spellingShingle | Ying Xu Yingxue Qi Zhongyu Lu Yuan Tan Dongsheng Chen Haijun Luo Navigating precision: the crucial role of next-generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor-positive, human epidermal growth factor Receptor2-negative early breast cancer Cancer Biology & Therapy Early breast cancer HR-positive HER2-negative adjuvant therapy recurrence risk assessment |
| title | Navigating precision: the crucial role of next-generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor-positive, human epidermal growth factor Receptor2-negative early breast cancer |
| title_full | Navigating precision: the crucial role of next-generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor-positive, human epidermal growth factor Receptor2-negative early breast cancer |
| title_fullStr | Navigating precision: the crucial role of next-generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor-positive, human epidermal growth factor Receptor2-negative early breast cancer |
| title_full_unstemmed | Navigating precision: the crucial role of next-generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor-positive, human epidermal growth factor Receptor2-negative early breast cancer |
| title_short | Navigating precision: the crucial role of next-generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor-positive, human epidermal growth factor Receptor2-negative early breast cancer |
| title_sort | navigating precision the crucial role of next generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor positive human epidermal growth factor receptor2 negative early breast cancer |
| topic | Early breast cancer HR-positive HER2-negative adjuvant therapy recurrence risk assessment |
| url | https://www.tandfonline.com/doi/10.1080/15384047.2024.2405060 |
| work_keys_str_mv | AT yingxu navigatingprecisionthecrucialroleofnextgenerationsequencingrecurrenceriskassessmentintailoringadjuvanttherapyforhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeearlybreastcancer AT yingxueqi navigatingprecisionthecrucialroleofnextgenerationsequencingrecurrenceriskassessmentintailoringadjuvanttherapyforhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeearlybreastcancer AT zhongyulu navigatingprecisionthecrucialroleofnextgenerationsequencingrecurrenceriskassessmentintailoringadjuvanttherapyforhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeearlybreastcancer AT yuantan navigatingprecisionthecrucialroleofnextgenerationsequencingrecurrenceriskassessmentintailoringadjuvanttherapyforhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeearlybreastcancer AT dongshengchen navigatingprecisionthecrucialroleofnextgenerationsequencingrecurrenceriskassessmentintailoringadjuvanttherapyforhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeearlybreastcancer AT haijunluo navigatingprecisionthecrucialroleofnextgenerationsequencingrecurrenceriskassessmentintailoringadjuvanttherapyforhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeearlybreastcancer |